Quick Answer
Regenerative Medical Technology Group Inc. reported Gross Profit of $2.82 million for the year ending 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +68.5% in Gross Profit from 2023 to 2024.
- This data is from Regenerative Medical Technology Group Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $13.2 thousand | Q2 2018: $3.2 thousand | Q3 2018: $4.9 thousand | Q1 2019: -$3.8 thousand | Q2 2019: -$7.8 thousand | Q3 2019: -$15.8 thousand | Q1 2020: -$799.00 | Q2 2020: $9.9 thousand | Q3 2020: $1.9 thousand | Q1 2021: -$10.3 thousand | Q2 2021: $3.9 thousand | Q3 2021: $76.5 thousand | Q1 2022: $106.3 thousand | Q2 2022: $147.0 thousand | Q3 2022: $264.9 thousand | Q1 2023: $536.8 thousand | Q2 2023: $253.8 thousand | Q3 2023: $450.3 thousand | Q1 2024: $569.0 thousand | Q2 2024: $526.9 thousand | Q3 2024: $747.1 thousand | Q1 2025: $943.9 thousand | Q2 2025: $585.8 thousand | Q3 2025: $501.6 thousand.
- Over the full 8 years of available data (2017 to 2024), Regenerative Medical Technology Group Inc.'s Gross Profit has grown by 11,455.5%.
- Historical annual values: Fiscal year 2024: $2.82 million | Fiscal year 2023: $1.68 million | Fiscal year 2022: $877.0 thousand | Fiscal year 2021: $150.1 thousand | Fiscal year 2020: $11.1 thousand | Fiscal year 2019: -$25.4 thousand | Fiscal year 2018: -$18.2 thousand | Fiscal year 2017: $24.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: